Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Brain for Business – A Brain for LifeA Background Scenario from Organisational Life

A Brain for Business – A Brain for Life: A Background Scenario from Organisational Life [There are many industries that one could choose for the purposes of presenting the story to follow, but here I choose an industry that I have long observed, namely the pharmaceutical industry. Novel and selective drugs are essential to my research work on the ageing brain and occasionally have proved very useful for the relief of minor headaches or other minor ailments! The pharmaceutical industry has many problems: competition for highly-qualified scientific staff, the high cost of bringing new drugs to the market, the risks of unexpected ‘adverse events’ caused by those drugs when administered to patients in a litigious society, a product pipeline that lacks new blockbuster drugs, a product development life cycle that can extend over decades, competition between companies for market shares and, increasingly, very severe competition from vendors of generic drugs when blockbuster pharmaceuticals come off patent. A wave of consolidation between many of the large pharmaceutical companies has taken place over the past two decades or so; this is a trend that is likely to continue. Opportunities for consolidation have revolved around finding partners that make logical sense in terms of the eventual goal of bringing novel drugs to the market. Do the potential partners match in terms of product pipeline, production facilities, novel bioassays, product distribution, logistics, cost-control and innovation? Is there hidden value in the large library of compounds, molecules and other agents that most of the pharmaceutical industry possesses? Will the eventual company have an internal and external logic that makes sense to investors, regulators, prescribers and patients? These issues are very complex and are difficult for one person to grasp in their entirety; in an important sense, mergers of these multi-billion dollar or euro entities with their tens of thousands of employees involve a complex act of faith, vision and facts.] http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

A Brain for Business – A Brain for LifeA Background Scenario from Organisational Life

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/a-brain-for-business-a-brain-for-life-a-background-scenario-from-PkFNHTy5xb
Publisher
Springer International Publishing
Copyright
© The Editor(s) (if applicable) and The Author(s) 2018
ISBN
978-3-319-49153-0
Pages
1 –7
DOI
10.1007/978-3-319-49154-7_1
Publisher site
See Chapter on Publisher Site

Abstract

[There are many industries that one could choose for the purposes of presenting the story to follow, but here I choose an industry that I have long observed, namely the pharmaceutical industry. Novel and selective drugs are essential to my research work on the ageing brain and occasionally have proved very useful for the relief of minor headaches or other minor ailments! The pharmaceutical industry has many problems: competition for highly-qualified scientific staff, the high cost of bringing new drugs to the market, the risks of unexpected ‘adverse events’ caused by those drugs when administered to patients in a litigious society, a product pipeline that lacks new blockbuster drugs, a product development life cycle that can extend over decades, competition between companies for market shares and, increasingly, very severe competition from vendors of generic drugs when blockbuster pharmaceuticals come off patent. A wave of consolidation between many of the large pharmaceutical companies has taken place over the past two decades or so; this is a trend that is likely to continue. Opportunities for consolidation have revolved around finding partners that make logical sense in terms of the eventual goal of bringing novel drugs to the market. Do the potential partners match in terms of product pipeline, production facilities, novel bioassays, product distribution, logistics, cost-control and innovation? Is there hidden value in the large library of compounds, molecules and other agents that most of the pharmaceutical industry possesses? Will the eventual company have an internal and external logic that makes sense to investors, regulators, prescribers and patients? These issues are very complex and are difficult for one person to grasp in their entirety; in an important sense, mergers of these multi-billion dollar or euro entities with their tens of thousands of employees involve a complex act of faith, vision and facts.]

Published: Aug 12, 2017

There are no references for this article.